Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21026170 | 0.84 | HRH3 (0.40) | HRH3NAMPTPIK3CDROCK2ROCK1 | |
| SCHEMBL25888121 | 0.83 | HRH3 (0.39) | HRH3NAMPTPIK3CDROCK2ROCK1 | |
| SCHEMBL20129353 | 0.83 | HRH3 (0.39) | HRH3NAMPTPIK3CDROCK2ROCK1 | |
| SCHEMBL23560035 | 0.82 | HRH3 (0.49) | HRH3NAMPTPIK3CDROCK2ROCK1 | |
| SCHEMBL23945274 | 0.81 | HRH3 (0.36) | HRH3 | |
| SCHEMBL18592313 | 0.81 | HRH3 (0.37) | HRH3NAMPTPIK3CDROCK2ROCK1 | |
| SCHEMBL20443206 | 0.81 | HRH3 (0.37) | HRH3NAMPTPIK3CDROCK2ROCK1 | |
| SCHEMBL25916228 | 0.81 | HRH3 (0.40) | HRH3NAMPTPIK3CDROCK2ROCK1 | |
| SCHEMBL24673647 | 0.80 | ROCK2 (0.39) | HRH3PIK3CDROCK2ROCK1CYP2D6 | |
| SCHEMBL24607658 | 0.80 | HRH3 (0.40) | HRH3NAMPTPIK3CDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | HRH3 4061/4885NAMPT 4424/4885PIK3CD 2656/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | HRH3 4061/4885NAMPT 4424/4885PIK3CD 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.